TheFactor-Y Ltd Redefines Global Investment and Innovation with CBaaS Model and First World For All Foundation

In a landmark move set to redefine global finance and entrepreneurship, TheFactor-Y Ltd has unveiled a global ecosystem that curates startup success and democratizes access to high-growth investments. The company’s groundbreaking Company-Building-as-a-Service (CBaaS) model systematically transforms unused intellectual property into scalable businesses, ensuring unprecedented returns for investors while fostering economic growth in up to 150 markets.

Rebalancing the Playing Field for Investors and Innovators

For decades, venture capital has been confined to elite hubs, disproportionately favoring startups from North America and Western Europe. As a result, game-changing innovations in low- and middle-income countries have been overlooked, stalling economic diversification and limiting global technological progress. TheFactor-Y Ltd’s CBaaS model plays a significant role in correcting this imbalance, offering a standardized investment framework that allows capital to flow efficiently into untapped regions and industries.

CBaaS eliminates uncertainties associated with traditional venture funding by de-risking the investment process and standardizing company-building. This ensures that high-impact solutions—ranging from sustainable energy technologies to medical breakthroughs—reach global markets, rather than being confined to venture capitalists’ preferred geographies.

A New Asset Class: Scalable, De-Risked Companies

Unlike conventional startup investments plagued by high failure rates, CBaaS leverages a centralized entrepreneurship model to industrialize company creation. This creates a new asset class: investment-ready, scalable companies built on top-tier intellectual property (IML Level 6+). With a direct-to-exit model, businesses launched through CBaaS are placed in the hands of major corporations, ensuring swift commercialization and liquidity.

For financial institutions, family offices, ultra-high net worth individuals, private equity firms, foundations, as well as ESG and sovereign wealth funds, this model presents an attractive alternative to traditional VC investments. CBaaS reduces key risks associated with startup investing while providing access to a diversified portfolio of businesses that are market-ready, high-growth, and impact-driven.

The Economic Impact: Job Creation, Market Expansion, and GDP Growth

Beyond financial returns, scaling TheFactor-Y Ltd’s CBaaS model will drive macroeconomic transformation. By channeling resources into underfunded regions, CBaaS will fuel large-scale job creation, foster industrial advancements, and expand global trade networks. The economic ripple effect will be profound:

Unprecedented job creation – Scaling CBaaS worldwide will generate employment opportunities on an industrial scale, particularly in emerging economies.

Diversified GDP growth – By unlocking innovation in non-traditional markets, CBaaS strengthens economic resilience and reduces dependency on single-industry economies.

Global market integration – Standardized entrepreneurship creates scalable businesses that transcend national boundaries, ensuring equal access to new technologies and services.

A Win-Win Model for Stakeholders: IP Holders, Investors, and Governments

CBaaS is designed to align incentives across all stakeholders:

Intellectual Property Holders (innovators, universities, research hubs) – Thousands of unused patents and research breakthroughs are transformed into commercially viable businesses, providing innovators with financial returns without the burden of company-building.

Investors – Capital is deployed efficiently into de-risked, high-growth companies with built-in exit strategies, optimizing returns while minimizing downside exposure.

Governments and Policymakers – By integrating CBaaS into national economic strategies, governments can accelerate economic growth, foster large-scale company creation and job generation, as well as attract foreign investment. On February 15th, TheFactor-Y will initiate its Government License program, which will be provided on a partnership basis exclusively to 20 countries. Through public-private partnerships, the franchise model provides a structured, high-impact approach to innovation, ensuring long-term economic returns.

Aligning Financial Growth with Global Impact

As part of its mission to drive sustainable economic change, TheFactor-Y Ltd reinvests up to 50% of profits into high-impact initiatives through its foundation, the Fyrst World For All Foundation. This includes funding poverty reduction programs, humanitarian aid efforts, and infrastructure projects that support long-term economic resilience. Moreover, CBaaS investments align with the UN’s Sustainability Agenda, prioritizing solutions that address global challenges such as climate change, water scarcity, food security, and social inequality.

A Meaningful Contribution to Social Progress and Combating Inequalities

The CBaaS model gives innovators from impoverished communities, minority groups, and underrepresented backgrounds—who have historically been shut out of venture capital and global startup ecosystems—an equal chance to bring their solutions to market. By eliminating investor bias and geographic barriers, CBaaS contributes to closing the gender gap in innovation.

The Future of Investment: A Scalable, Inclusive Economy

TheFactor-Y Ltd is creating a new economic framework where innovation is not constrained by geography, capital access, or traditional startup inefficiencies.

With operations in 22+ countries and an expansion plan reaching 150+ markets, the company is systematically building thousands of scalable businesses that will redefine global trade and investment. For financial leaders looking to capitalize on the next wave of high-growth, impact-driven ventures, TheFactor-Y Ltd presents an unparalleled opportunity to be at the forefront of a new economic paradigm. For more information about TheFactor-Y Ltd please visit www.thefactor-y.com and www.cbaas.com.

More information on The First World For All Foundation can be found at: www.fyrst.world.

Media Contact
Company Name: CBaaS
Contact Person: Philipp Assmus
Email: Send Email
Country: United Kingdom
Website: https://cbaas.com/

Peter Doran Joins the Board of Directors at International Real Estate Partners (IREP) as Group Chief Operating Officer

International Real Estate Partners (IREP), a leading global provider of integrated real estate and facilities management solutions, proudly announces the appointment of Peter Doran to its Board of Directors as Group Chief Operating Officer.

Peter Doran, a highly accomplished RICS-qualified executive with over three decades of experience, brings extensive expertise in unlocking value through the transformation and optimization of global property portfolios. As a trusted strategic leader in real estate management, Peter is known for his exceptional long-term planning capabilities, strong commercial acumen, and ability to drive growth, efficiencies and results.

Peter has held senior leadership roles in Technology, Manufacturing, and advisory sectors. As Senior VP of Corporate Real Estate at GEA AG and President of Global Corporate Services at Newmark Knight Frank, transformed the Global Corporate Services division into a high-performing, revenue and profit-generating unit. At GEA AG, he led global property strategy and advanced sustainability initiatives, including renewable energy projects for net-zero carbon targets.

“I am truly honoured to join the Board of Directors at IREP and contribute to its mission of delivering innovative and sustainable real estate solutions worldwide,” said Peter Doran.

“IREP’s global vision and commitment to excellence align closely with my passion for driving impactful outcomes in the real estate and facilities management industry.

”IREP’s leadership team expressed enthusiasm about Peter’s appointment.

“Peter’s strategic mindset and extensive global expertise in real estate and facilities management will undoubtedly strengthen our organization and enhance our ability to deliver exceptional value to clients worldwide,” said Kenny McCrea Chairman & CEO, IREP.

About International Real Estate Partners (IREP)

Headquartered in Dubai, UAE, International Real Estate Partners specializes in providing innovative and sustainable solutions in real estate management and facilities services. Operating across multiple countries, IREP empowers businesses to optimize their property portfolios and achieve operational excellence.

Media Contact
Company Name: International Real Estate Partners (IREP)
Contact Person: Sana Gul
Email: Send Email
Phone: +92 323 797 0001
Address:Office 608, 6th Floor, Indigo Icon Tower
City: Dubai
Country: United Arab Emirates
Website: https://irepartners.com

Pickleball Prep Elevates Pickleball Style With Colorful Fashion-Forward Apparel and Accessories

This fashion brand injects color and life into that next pickleball game with its delightful hues and designs.

New York, NY – February 18, 2025 – Pickleball Prep, a female-founded athleisure brand, turns any pickleball game up a notch with its vibrant, fashion-forward approach. Offering a curated collection of stylish and functional pickleball gear, Pickleball Prep empowers women and girls to express themselves confidently on and off the court.

Serve in Style with Pickleball Prep!

A Preppy Pickleball Bag for Every Player

Pickleball Prep understands that every player has a unique sense of style. Whether sporty, preppy, or trendy, the brand’s collection of pickleball bags seamlessly combines practicality and elegance, ensuring players can carry their essentials with ease and flair.

Game-Changing Pickleball Paddles

Designed for both beginners and experienced players, Pickleball Prep paddles are lightweight yet durable, providing effortless maneuverability and lasting performance. Available in nine bold colors, these paddles also come in a special child-size version, making pickleball a fun and stylish activity for the whole family.

Score Style Points On and Off the Court

Pickleball Prep’s preppy sweaters bring effortless style to any game, while high-quality visors offer sun protection and comfort, allowing players to stay cool and focused.

For those searching for the perfect gift for a pickleball enthusiast, Pickleball Prep offers a collection of vibrant accessories designed to impress even the most stylish players.

A Complete Suite of Matching Pickleball Essentials

Pickleball Prep’s vibrant product line includes:

  • Pickleball paddles – Lightweight, durable, and easy to handle

  • Paddle covers – Stylish protection for paddles

  • Pickleball bags – Functional and fashion-forward

  • Court towels – Soft, absorbent, and high-quality

  • Visors and hats – Designed to keep the sun out while looking chic

  • Preppy sweaters – A must-have for pickleball enthusiasts

  • Kid-sized paddles – Perfectly designed for young players

  • Pickleball accessories and gifts – Including notepads, keychains, tumblers, and journals

Shop Today

Explore the collection at www.pickleballprep.com and follow @‌pickleball_prep on Instagram and @‌pickleballprep on TikTok for the latest updates.

Pickleball Prep

About Pickleball Prep

Founded in 2024 by Anne Cynar, Pickleball Prep was created to fill a gap in the market for high-quality pickleball gear that seamlessly blends style and function. As a lifelong athlete and entrepreneur, Anne believes in the power of sports to build confidence, community, and an active lifestyle. Pickleball Prep’s bold, fashion-forward designs reflect that philosophy, giving players a way to serve in style.

Pickleball Prep is available at select retailers, including Buckskill Tennis and Winter Club, Gubbins Running Ahead, Gubbins The Perfect Fit, and Set Point Tennis in East Hampton and Southampton, NY.

Media Contact
Company Name: Pickleball Prep
Contact Person: Anne Cynar
Email: Send Email
Country: United States
Website: http://www.pickleballprep.com/

Cancer Caregiving with Heart and Humor: Award-winning Novelist and Emmy-Nominated Producer Maren Higbee Shares Her Journey in A Cancer Patient’s Wife

Inspired by Maren Higbee’s real-life cancer journey with her husband, A Cancer Patient’s Wife is a powerful reminder that amidst life’s hardest battles, it’s humor, love, and the people who stand by you that make all the difference, even when healing feels impossible.

Maren Higbee is an Emmy-nominated producer, award-winning novelist, and storyteller who’s spent her career crafting memorable narratives. Her work spans from hit TV shows like The Deadliest Catch, Oprah’s Big Give, and Jockeys, to novels including Lana Fray and the Grand Plan and the cozy mystery novella, The Clock Strikes One.

In 2017, Maren’s life was upended when her husband was diagnosed with Non-Hodgkin’s Lymphoma, facing a 6-inch tumor and the whirlwind of hospitals and chemo. Searching for humor and humanity in the caregiving experience, she turned to her writing. Her latest novel, A Cancer Patient’s Wife, is a fictionalized version of their journey, blending raw honesty with moments of levity to support others facing cancer or caregiving. With her trademark humor and heart, Maren hopes to bring relief, inspiration, and maybe even a laugh to those navigating life’s toughest challenges. This one-on-one interview shares Maren’s background and experience writing A Cancer Patient’s Wife.

Tell us about A Cancer Patient’s Wife.

Luke’s cancer diagnosis is a twist that video producer Maggie never saw coming.

As the married couple navigate a maze of long hospital stays, tests, and a life completely interrupted, Luke holds true to his stoic nature while Maggie struggles to embrace her new starring role as a cancer caregiver.

With a cast of characters—including their German shepherd, Westy—spanning supportive to downright despicable, Luke and Maggie learn that sometimes healing from an illness is only half the battle.

How do you fight the turmoil? Why, with humor of course!

What inspired you to write A Cancer Patient’s Wife?

When my husband was diagnosed with Lymphoma, I went into full researcher mode, looking for support and information to be the best caregiver I could. However, as I searched for materials, most of what I found was either too clinical or just plain boring.

As a writer who’s spent years crafting stories for TV and commercials—and who had just published my first book, Lana Fray and the Grand Plan—I figured, why not use those skills to help others?

So, I fictionalized our story, partly to make it more relatable and partly to protect the identities of the, let’s say, “creative” people who handled our cancer journey in their own quirky ways. This book is my way of saying, “I get it, caregiving is hard, weird, and sometimes downright hilarious.”

My hope is that it brings comfort, laughs, and maybe a little sanity to anyone navigating this unpredictable, emotional rollercoaster.

What is one message you would like readers to remember?

In writing this book, my goal is for readers to find inspiration and support, no matter what challenges they’re facing.

For cancer caregivers and patients in specific, I want you to see yourselves in these pages and feel a little less alone, maybe even a little lighter. This journey is tough, and sometimes the only way through is to laugh—even when nothing feels funny. Because let’s be honest, life has a way of throwing you into absurd, frustrating, and downright ridiculous situations, and it’s okay to laugh at yourself or the chaos around you. In fact, it might be the best medicine we have.

If this book can bring even a moment of relief, a smile, or the realization that you’re stronger than you think, then I’ve done what I set out to do.

Purchasing the Book

A Cancer Patient’s Wife has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Ashley Yesayan, CEO and founder of OneVillage.io, cancer survivor and caregiver writes, “Maren Higbee is a master storyteller . . . her book is the perfect dose of humor and strength for caregivers looking for a path forward.” In addition, author Martina Dalton writes, “A heartwarming and sometimes heartbreaking novel, A Cancer Patient’s Wife offers a rare and intimate glimpse into a caregiver’s life.

The book is available for sale on Amazon, Barnes & Noble and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Cancer-Patients-Wife-Maren-Higbee/dp/1633153126/

To connect with Maren and learn more about her work, visit: https://www.marenhigbee.com/. You can also find her on Facebook, LinkedIn and BlueSky.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cancer Caregiving with Heart and Humor: Award-winning Novelist and Emmy-Nominated Producer Maren Higbee Shares Her Journey in A Cancer Patient’s Wife

The Midlife Male Handbook A Man’s Guide to Thriving Through Andropause

The single biggest killer of men after 50 is heart disease, yet males aged 50 to 54 have the highest suicide rate of all.

The single biggest killer of men after 50 is heart disease, yet males aged 50 to 54 have the highest suicide rate of all.

Men who commit suicide tend to have lower testosterone levels. Low testosterone is not only a risk of heart disease, but by midlife men are starting to feel the effects of low testosterone more than at any other time in their life, which can bring a whole host of symptoms – physical, emotional, mental and psychological – also known as the ‘andropause’.

Not only that, but testosterone levels are falling. Testosterone levels are down just 50% in 20 years… The average 22-year-old today has lower testosterone than the average 70 year old had just 50 years ago.

Yet testosterone is stigmatised.

James Davis says we need to start talking about it, undo the stigma, and start helping men not just survive, but thrive. And this is why he wrote this book.

The Midlife Male Handbook is a comprehensive resource designed to help men reclaim their vitality during andropause. This book goes beyond addressing just the physical symptoms of midlife, like decreased energy, by also delving into the emotional and psychological challenges that often accompany this stage.

With practical advice rooted in the latest research, it offers a holistic approach to managing the andropause, including a 30-day program focused on diet, exercise, and mental well-being. Whether you’re facing fatigue, mood swings, or relationship strain, this guide provides actionable strategies to help men not just survive but thrive in midlife. It’s an invaluable tool for men over 40 and their loved ones, offering the insights needed to turn into a mid-life crisis into an opportunity for renewed health and happiness.

About the author:

James Davis is one half of the husband-and-wife team behind multi-award winning coaching and fitness company 38 Degrees North and The MidlifeMentors. The couple are highly regarded as leading experts in midlife health and happiness. Claire & James – AKA The Midlife Mentors – are also public speakers and feature regularly in national press.

They have hosted a highly successful podcast The Midlife Mentors since 2019 which is now in the top 1.5% of podcasts globally. The aim of the podcast is to lift the lid on their no-nonsense approach to thriving after 40 – in mind, body and soul.

Their science-based approach leverages their experience in psychology, NLP, stress management, personal training, nutrition and life/business coaching. They’re also hormone specialists and Level 1 certified by the International Menopause Society.

Over a career spanning a decade James and Claire have trained thousands of clients and they are incredibly passionate about offering an anti-fad approach to the health and wellness narrative. No fancy diets or pseudo-science. Just authentic, balanced information based on a wealth of professional and personal experience.

Championing the andropause and empowering midlife men with the knowledge and tools to make meaningful changes to their lives is a particular passion for James and he’s proud to work with corporations like CitiBank, Morrisons and KPMG delivering workshops and programmes around andropause and other health subjects.

For a review copy, press images or interview time with James, please contact:

Olivia Pearce – Read Maxwell Communications – olivia@readmaxwell.co.uk

To see more information about the book, please visit:

https://www.amazon.com/Midlife-Male-Handbook-Thriving-Andropause-ebook/dp/B0DM7JXKPM/

Author: James Davis

The Midlife Male Handbook

ISBN G78-0-G12106-3G-7

£17.00

Media Contact
Company Name: Read Maxwell Communications
Contact Person: Olivia Pearce
Email: Send Email
Country: United States
Website: https://www.amazon.com/Midlife-Male-Handbook-Thriving-Andropause-ebook/dp/B0DM7JXKPM/

Idiopathic Membranous Nephropathy Market, 2034 | Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astell

“Idiopathic Membranous Nephropathy Market 2034”
The Idiopathic Membranous Nephropathy market growth is driven by factors like increase in the prevalence of Idiopathic Membranous Nephropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Idiopathic Membranous Nephropathy market report also offers comprehensive insights into the Idiopathic Membranous Nephropathy market size, share, Idiopathic Membranous Nephropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Idiopathic Membranous Nephropathy market size growth forward.

Some of the key highlights from the Idiopathic Membranous Nephropathy Market Insights Report:

  • Several key pharmaceutical companies, including Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others, are developing novel products to improve the Idiopathic Membranous Nephropathy treatment outlook.

  • The Idiopathic Membranous Nephropathy (IMN) market in the 7MM is projected to reach approximately USD 1,000 million by 2034. In 2023, the United States held the largest market share, generating around USD 88 million, surpassing EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

  • IMN is a major glomerular disease characterized by excessive protein loss in the urine (nephrotic syndrome) and is primarily autoimmune in nature. Currently, there are no approved treatments specifically for IMN, with management focused on supportive care. However, the market is expected to grow due to improved uptake of existing drugs, upcoming therapy launches, and increased awareness.

  • In 2023, the estimated total prevalent IMN population in the 7MM was approximately 71,000 cases. The US accounted for about 40% of these cases, while EU4 and the UK collectively made up around 35%, and Japan contributed approximately 25%, making it the second-largest region after the US.

  • Several emerging therapies are in development, including TNT119, ALPN-303, MOR202, SNP-ACTH (1-39) Gel, and GAZYVA. Notably, in October 2023, the FDA granted Breakthrough Therapy designation (BTD) to felzartamab for primary membranous nephropathy. Additionally, in June 2023, the FDA awarded orphan drug designation (ODD) to SNP-ACTH (1-39) gel for treating primary membranous nephropathy.

  • In July 2024, Biogen finalized its acquisition of Human Immunology Biosciences (HI-Bio). Earlier, in June 2022, HI-Bio had entered an agreement with MorphoSys AG to develop and commercialize the anti-CD38 antibody felzartamab.

  • As per DelveInsight analysis, the Idiopathic Membranous Nephropathy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Idiopathic Membranous Nephropathy Market Landscape

Idiopathic Membranous Nephropathy Overview

Idiopathic Membranous Nephropathy is a common glomerular disease closely linked to nephrotic syndrome. It occurs when the immune system mistakenly attacks the glomeruli, resulting in excessive protein loss in urine (proteinuria), swelling (edema), and, in some cases, progression to kidney failure. The term “idiopathic” indicates that no clear underlying cause has been identified, though the condition may also develop due to autoimmune disorders or infections. This disease primarily affects adults, particularly middle-aged men, and manifests through symptoms such as foamy urine, leg and abdominal swelling, and weight gain caused by fluid retention.

Diagnosis involves a combination of clinical evaluation and laboratory tests. Urine analysis detects proteinuria, often exceeding 3.5 g/day, while blood tests assess kidney function, low albumin levels (hypoalbuminemia), and lipid imbalances (dyslipidemia), which are typical of nephrotic syndrome. A kidney biopsy remains the gold standard for diagnosis, revealing immune complex deposits along the glomerular capillary walls. Additionally, serological testing for antibodies like anti-PLA2R helps distinguish primary Idiopathic Membranous Nephropathy from secondary forms, aiding in precise treatment decisions.

Do you know the treatment paradigms for different countries? Download our Idiopathic Membranous Nephropathy Market Sample Report

Idiopathic Membranous Nephropathy Epidemiology Insights

  • In 2023, the United States represented approximately 40% of the total prevalent cases of Idiopathic Membranous Nephropathy across the 7MM.

  • Meanwhile, Japan’s prevalence data indicates a relatively steady trend projected over the forecast period from 2024 to 2034.

Idiopathic Membranous Nephropathy Epidemiology Segmentation

DelveInsight’s Idiopathic Membranous Nephropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Idiopathic Membranous Nephropathy historical patient pools and forecasted Idiopathic Membranous Nephropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Idiopathic Membranous Nephropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Idiopathic Membranous Nephropathy Prevalence

  • Age-Specific Idiopathic Membranous Nephropathy Prevalence

  • Gender-Specific Idiopathic Membranous Nephropathy Prevalence

  • Diagnosed and Treatable Cases of Idiopathic Membranous Nephropathy

Visit for more @ Idiopathic Membranous Nephropathy Epidemiological Insights

Idiopathic Membranous Nephropathy Market Outlook

Key companies, including Hoffmann-La Roche, HI-Bio, Cerium Pharmaceuticals, BeiGene, and others, are advancing their lead candidates through various stages of clinical development. Their goal is to explore these products as treatments for Idiopathic Membranous Nephropathy.

In the 7MM, MOR202 (felzartamab) is projected to achieve the highest market revenue, reaching approximately USD 500 million by 2034. Among the EU4 and the UK, Germany had the largest market share, with an estimated value of around USD 10 million in 2023. Japan’s market is anticipated to grow to approximately USD 70 million by 2034. In 2023, Rituximab generated roughly USD 50 million in revenue across the 7MM.

Idiopathic Membranous Nephropathy Emerging Drugs

  • GAZYVA (obinutuzumab): Hoffmann-La Roche

  • SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

Idiopathic Membranous Nephropathy Key Companies

  • Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others

For more information, visit Idiopathic Membranous Nephropathy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Idiopathic Membranous Nephropathy Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Idiopathic Membranous Nephropathy, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Idiopathic Membranous Nephropathy epidemiology in the 7MM

  • Idiopathic Membranous Nephropathy marketed and emerging therapies

  • Idiopathic Membranous Nephropathy companies

  • Idiopathic Membranous Nephropathy market drivers and barriers

Table of Contents:

1 Idiopathic Membranous Nephropathy Market Key Comprehensive Insights

2 Idiopathic Membranous Nephropathy Market Report Introduction

3 Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy

4 Idiopathic Membranous Nephropathy Market Analysis Overview at a Glance

5 Executive Summary of Idiopathic Membranous Nephropathy

6 Idiopathic Membranous Nephropathy Epidemiology and Market Methodology

7 Idiopathic Membranous Nephropathy Epidemiology and Patient Population

8 Idiopathic Membranous Nephropathy Patient Journey

9 Idiopathic Membranous Nephropathy Treatment Algorithm, Idiopathic Membranous Nephropathy Current Treatment, and Medical Practices

10 Key Endpoints in Idiopathic Membranous Nephropathy Clinical Trials

11 Idiopathic Membranous Nephropathy Marketed Therapies

12 Idiopathic Membranous Nephropathy Emerging Therapies

13 Idiopathic Membranous Nephropathy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Idiopathic Membranous Nephropathy

16 Idiopathic Membranous Nephropathy Market Key Opinion Leaders Reviews

18 Idiopathic Membranous Nephropathy Market Drivers

19 Idiopathic Membranous Nephropathy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Idiopathic Membranous Nephropathy Epidemiology 2034

DelveInsight’s “Idiopathic Membranous Nephropathy – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Idiopathic Membranous Nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Idiopathic Membranous Nephropathy Pipeline 2024

“Idiopathic Membranous Nephropathy Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Idiopathic Membranous Nephropathy market. A detailed picture of the Idiopathic Membranous Nephropathy pipeline landscape is provided, which includes the disease overview and Idiopathic Membranous Nephropathy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Membranous Nephropathy Market, 2034 | Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astell

Leading the Way in Continuous Improvement Procedure: Compliance Expert Eases Procedure with Step-by-Step ISO Guidelines

Leading the Way in Continuous Improvement Procedure: Compliance Expert Eases Procedure with Step-by-Step ISO Guidelines
Continuous improvement is the key to achieving success in any organization, and Endeavour Technical Limited is an essential tool to implement this procedure.

The International Organisation for Standardization (ISO) provides a framework for ensuring consistent and reliable processes to help businesses improve their operational efficiency. A key component of ISO standards is the focus on continuous improvement, which helps companies stay competitive and responsive to changing markets.

Richard Keen, Compliance Director of Endeavour Technical Limited, offers insights on how organizations can achieve their goals through a continuous improvement procedure. With extensive experience working with a range of organizations of all sizes across a variety of industries, Mr. Keen’s expertise in ISO procedure enables him to guide organizations through the process of continuous improvement, identifying areas for improvement, implementing changes, and measuring the impact of those changes.

The purpose of the framework for continuous improvement is to enable businesses to continually review and refine processes, ensuring objectives, deliverables, and customer service standards are met. By implementing it, businesses can ensure they stay up-to-date with changing market conditions and customer expectations.

A one-size-fits-all solution simply does not exist, but Endeavour Technical Limited’s guidelines provide a step-by-step guide to help the ISO project manager develop a continuous improvement plan tailored to the organization. Doing so ensures that the business is working towards continuous improvement and is committed to providing quality products and services to its customers.

As such, Endeavour Technical Limited’s approach is based on a thorough understanding of ISO procedure and a focus on collaboration between the implementing company and its customers. The checklist helps the organization to identify areas where it excels and areas where improvement is needed. The checklist provides a structured approach to implementing the ISO Continuous Improvement Procedure, making the process more efficient and effective.

For more information, visit https://www.iso-9001-checklist.co.uk/10.3-continual-improvement.htm

It is crucial that the project drivers invest the time to understand the organization’s strengths and weaknesses and specific requirements to achieve the decided outcome. Many organisations have experienced significant improvements in their operations. There are countless examples of manufacturing companies struggling with a high level of defects before implementing ISO and recording a 50% reduction in defect rate after its ISO certification.

The ISO Continuous Improvement Procedure is an ongoing process. The organization needs to continually review and improve its processes to ensure that it is meeting the standard guidelines. The Endeavour Technical Limited helps the organization identify areas where it can improve its processes and provides the matrix to implement the improvements.

The ISO Continuous Improvement Procedure is not just about meeting the standard requirements. It is about providing quality products and services to customers. Endeavour Technical Limited helps the business to focus on customer satisfaction and to ensure that its products and services meet the needs of its customers.

Overall, continuous improvement will enable businesses to achieve real, measurable improvements in their operations. Organizations can ensure they stay competitive and responsive to changing market conditions while delivering value to their customers.

Endeavour Technical Limited’s templates and guidelines are essential for any organization intending to successfully implement the ISO Continuous Improvement Procedure. They play a crucial role in ensuring that any organization’s ISO project managers will be effectively guided to meet the standard guidelines of ISO 9001.

About the Company:

Endeavour Technical Limited is an ISO company based in London, UK. The company is dedicated to writing and developing ISO templates for customers worldwide. Endeavour Technical Limited is committed to providing high-quality products and services and excellent customer service. ISO-9001-Checklist.co.uk is a leading provider of quality management resources, including checklists, templates, and guides for ISO 9001 compliance.

Media Contact
Company Name: Endeavour Technical Limited
Contact Person: Richard Keen
Email: Send Email
Phone: 0845 054 2886
Address:71–75 Shelton Street, Covent Garden
City: London WC2H 9JQ
Country: United Kingdom
Website: https://www.iso-9001-checklist.co.uk/

Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapi

“Epidermolysis Bullosa Market 2034”
The Epidermolysis Bullosa market growth is driven by factors like increase in the prevalence of Epidermolysis Bullosa, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Epidermolysis Bullosa market report also offers comprehensive insights into the Epidermolysis Bullosa market size, share, Epidermolysis Bullosa epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Epidermolysis Bullosa market size growth forward.

Some of the key highlights from the Epidermolysis Bullosa Market Insights Report:

  • Several key pharmaceutical companies, including Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics, and others, are developing novel products to improve the Epidermolysis Bullosa treatment outlook.

  • In September 2024, a small real-world study showed that Janus kinase (JAK) inhibitors, such as upadacitinib and baricitinib, were more effective than dupilumab in reducing itching and skin lesions in individuals with epidermolysis bullosa pruriginosa (EBP). Among five patients treated with dupilumab, only two experienced a 50% reduction in itching, and none achieved complete relief. In contrast, all five patients treated with JAK inhibitors reported full relief from itching.

  • In December 2023, the FDA approved the use of Filsuvez, a topical gel containing birch triterpenes from Chiesi Global Rare Diseases, for treating partial thickness wounds in patients with junctional and dystrophic epidermolysis bullosa (EB). This approval marks Filsuvez as the only FDA-approved treatment for junctional EB. The decision was based on results from the phase 3 EASE trial, which involved 223 participants across 58 sites in 28 countries, including a three-month randomized controlled phase and a 24-month open-label phase.

  • In 2023, the Epidermolysis Bullosa (EB) market was largest in the US, with a market size of approximately USD 1,300 million, and it is expected to grow further by 2034. Epidermolysis Bullosa simplex (EBS) is the least severe form, with many individuals experiencing improvements as they age, while recessive dystrophic Epidermolysis Bullosa is considered the most severe type. In 2023, over 30% of EB cases were attributed to dystrophic EB, while only 5% were linked to junctional EB.

  • Currently, there are limited effective treatments for EB, and management primarily focuses on supportive care, including wound care, pain and itch management, infection control, nutritional support, and treating complications. Stem cell-based therapies, particularly ABCB5+ mesenchymal stromal cells (MSCs), are gaining attention due to their immunomodulatory and anti-inflammatory properties, showing promise for treating chronic inflammatory conditions like EB.

  • Japan is leading in cell therapy development, having approved the first cell therapy for EB, JACE (human epidermal cell sheet), in December 2018. There is also significant competition in gene therapy development for EB, with Krystal leading by securing FDA approval for VYJUVEK, effective for both recessive and dominant forms of the disease. Abeona’s EB-101, a similar gene therapy, also shows promising results. Although Krystal is a year ahead in development, both therapies are vying for market share.

  • Despite these advancements, there remains a significant unmet need for EB therapies, highlighting the importance of continued research and development to improve treatment options and the quality of life for EB patients globally.

  • As per DelveInsight analysis, the Epidermolysis Bullosa market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Epidermolysis Bullosa Market Landscape

Epidermolysis Bullosa Overview

Epidermolysis Bullosa (EB) is a genetic skin disorder marked by fragile skin that blisters easily due to minimal friction or trauma. It is caused by mutations in genes that affect skin proteins essential for structural integrity. The severity of EB varies, from mild cases to life-threatening forms, depending on the subtype. The patient journey typically begins with symptoms like frequent blistering and slow wound healing, prompting caregivers to seek medical attention. Diagnosis is confirmed through skin biopsy and genetic testing to classify the subtype. Following diagnosis, a multidisciplinary team, including dermatologists, wound care specialists, nutritionists, and physiotherapists, develops a treatment plan. Emotional support is also important to help patients cope with the condition. Long-term care and regular follow-ups are essential to monitor skin health and prevent complications. Early diagnosis plays a key role in improving the patient’s quality of life.

Do you know the treatment paradigms for different countries? Download our Epidermolysis Bullosa Market Sample Report

Epidermolysis Bullosa Epidemiology Insights

  • In 2023, the United States had the highest prevalence of Epidermolysis Bullosa, making up approximately 65% of the total cases across the 7MM. Meanwhile, the EU4 countries and the UK accounted for around 30%, and Japan represented about 5% of the total prevalence.

  • Within the EU4 and UK regions, the United Kingdom had the highest number of cases, followed by Germany, while Spain had the fewest cases in 2023.

Epidermolysis Bullosa Epidemiology Segmentation

DelveInsight’s Epidermolysis Bullosa market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Epidermolysis Bullosa historical patient pools and forecasted Epidermolysis Bullosa patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Epidermolysis Bullosa Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Epidermolysis Bullosa Prevalence

  • Age-Specific Epidermolysis Bullosa Prevalence

  • Gender-Specific Epidermolysis Bullosa Prevalence

  • Diagnosed and Treatable Cases of Epidermolysis Bullosa

Visit for more @ Epidermolysis Bullosa Epidemiological Insights

Epidermolysis Bullosa Market Insights

Ongoing research into Epidermolysis Bullosa (EB) treatments includes various approaches like gene therapies, cell-based therapies, recombinant protein therapies, and small molecule treatments. Gene therapies, especially VYJUVEK, the first FDA-approved topical gene therapy, are progressing significantly. Other contenders, including Abeona and Castle Creek Biosciences, also aim to introduce COL7A1 into the body.

VYJUVEK uses herpes simplex virus type 1 (HSV-1) as a gene therapy vector, which doesn’t integrate into the host’s genome, reducing the risk of cancer. JACE, approved in 2018, was the first cell therapy approved for EB. Additionally, stem cell therapies, particularly those using ABCB5+ mesenchymal stromal cells, show promise due to their immune-modulatory properties, aiding chronic wound healing. Other cell-based treatments, such as ISN001 from Ishin Pharma and ALLO-RV-LAMB3-transduced epidermal stem cells from Holostem Terapie Avanzate, are also in development.

Epidermolysis Bullosa Marketed Drugs

  • VYJUVEK (beremagene geperpavec): Krystal Biotech

  • FILSUVEZ (oleogel-S10): Chiesi Farmaceutici

Epidermolysis Bullosa Emerging Drugs

  • EB-101: Abeona Therapeutics

  • D-Fi (dabocemagene autoficel): Castle Creek Biosciences

Epidermolysis Bullosa Key Companies

  • Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim, Shionogi, Phoenix Tissue Repair (BridgeBio Pharma, Inc), Menlo Therapeutics, JCR Pharmaceuticals, Amicus Therapeutics, and others

For more information, visit Epidermolysis Bullosa Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Epidermolysis Bullosa Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Epidermolysis Bullosa, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Epidermolysis Bullosa epidemiology in the 7MM

  • Epidermolysis Bullosa marketed and emerging therapies

  • Epidermolysis Bullosa companies

  • Epidermolysis Bullosa market drivers and barriers

Table of Contents:

1 Epidermolysis Bullosa Market Key Comprehensive Insights

2 Epidermolysis Bullosa Market Report Introduction

3 Competitive Intelligence Analysis for Epidermolysis Bullosa

4 Epidermolysis Bullosa Market Analysis Overview at a Glance

5 Executive Summary of Epidermolysis Bullosa

6 Epidermolysis Bullosa Epidemiology and Market Methodology

7 Epidermolysis Bullosa Epidemiology and Patient Population

8 Epidermolysis Bullosa Patient Journey

9 Epidermolysis Bullosa Treatment Algorithm, Epidermolysis Bullosa Current Treatment, and Medical Practices

10 Key Endpoints in Epidermolysis Bullosa Clinical Trials

11 Epidermolysis Bullosa Marketed Therapies

12 Epidermolysis Bullosa Emerging Therapies

13 Epidermolysis Bullosa: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Epidermolysis Bullosa

16 Epidermolysis Bullosa Market Key Opinion Leaders Reviews

18 Epidermolysis Bullosa Market Drivers

19 Epidermolysis Bullosa Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Epidermolysis Bullosa Epidemiology 2034

DelveInsight’s “Epidermolysis Bullosa – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Epidermolysis Bullosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epidermolysis Bullosa Pipeline 2024

“Epidermolysis Bullosa Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Epidermolysis Bullosa market. A detailed picture of the Epidermolysis Bullosa pipeline landscape is provided, which includes the disease overview and Epidermolysis Bullosa treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epidermolysis Bullosa Market Expected to rise, 2034 | Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, Fibrocell Technologies, RHEACELL GmbH, Holostem Terapi

Monjur and MSPAlliance Announce Strategic Partnership to Improve Cybersecurity and Compliance for MSPs

Southlake, Texas – February 18, 2025 – Monjur, renowned for its innovative contract solutions for managed service providers (MSPs), has joined forces with MSPAlliance, the world’s largest international cloud and managed services association. This strategic partnership, founded on the extensive expertise of both Monjur and MSPAlliance, will see the two entities promote and market each other’s solutions. They will also integrate Monjur’s expertise in customer contracting with the MSPAlliance Cyber Verify certification program.

With Monjur’s legal technology, Cyber Verify can help MSPs apply a holistic approach to proving trust, accountability, and compliance with industry standards. The partnership underscores the unwavering commitment of both Monjur and MSPAlliance to elevating cybersecurity and compliance levels within the MSP industry, demonstrating a profound understanding of the unique challenges that MSPs face and providing reassurance to the audience.

“Monjur’s partnership with MSPAlliance is a continuation of the strong, two-decade-long relationship with MSPAlliance,” said Rob Scott, CEO at Monjur. “Through our collaboration, we provide MSPs with the much-needed legal protection and the cybersecurity capability required to grow their businesses securely.”

Cyber Verify is an MSP compliance program purpose-built for MSPs, based on an MSP standard (the Unified Certification Standard for Cloud & Managed Service Providers), and capable of unleashing powerful MSP Compliance as a Service, vCISO, and vCIO services. Through this partnership, Monjur’s customers can obtain the CyberVerify program directly from the company, enhancing their cybersecurity position and providing a competitive edge in the market.

“Monjur possesses a strong grasp of MSP legal agreements and risk mitigation, making them a great fit for our Cyber Verify certification,” said Charles Weaver, CEO of MSPAlliance. “With this partnership, we can offer MSPs legal and cybersecurity audits to help them meet industry standards and build client trust.”

This collaboration will help MSPs work more effectively and with robust security as the digital world becomes increasingly complex. Visit Monjur’s website to learn more about them and their legal services. Visit MSPAlliance’s website to learn more about Cyber Verify. Email Thomas Mustac from OtterPR at thomas.mustac@otterpr.com for media inquiries or further information.

About Monjur

Monjur is redefining how businesses consume legal services by offering simple, scalable solutions tailored to the unique challenges of today’s recurring revenue-based industries. Unlike traditional legal services, Monjur provides predictable, subscription-based pricing and on-demand access to legal expertise, eliminating the uncertainty of hourly billing and costly retainers.

About MSPAlliance

MSPAlliance® is a global industry association and accrediting body for the Cyber Security, Cloud Computing, and Managed Services Provider (MSP) industry. Established in 2000, MSPAlliance has been dedicated to helping MSPs become better service providers. Collaborating with corporate members worldwide, MSPAlliance works towards setting standards, policies, and best practices, benefiting its members and governments alike.

For more information, visit www.mspalliance.com

Media Contact
Company Name: Otter Public Relations
Contact Person: Thomas Mustac
Email: Send Email
Address:136 4th St N Ste 201
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Monjur and MSPAlliance Announce Strategic Partnership to Improve Cybersecurity and Compliance for MSPs

Peripheral Neuropathic Pain Market Expected to rise, 2034 | Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex

“Peripheral Neuropathic Pain Market 2034”
The Peripheral Neuropathic Pain market growth is driven by factors like increase in the prevalence of Peripheral Neuropathic Pain, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Peripheral Neuropathic Pain market report also offers comprehensive insights into the Peripheral Neuropathic Pain market size, share, Peripheral Neuropathic Pain epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Peripheral Neuropathic Pain market size growth forward.

Some of the key highlights from the Peripheral Neuropathic Pain Market Insights Report:

  • Several key pharmaceutical companies, including Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others, are developing novel products to improve the Peripheral Neuropathic Pain treatment outlook.

  • In November 2023, Lexicon Pharmaceuticals announced the enrollment of the first patient in the PROGRESS study, a Phase IIb, dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial with an open-label extension, evaluating LX9211 for diabetic peripheral neuropathic pain.

  • In 2023, the Peripheral Neuropathic Pain (PNP) market in the 7MM was valued at approximately USD 12 billion, with projections indicating significant growth by 2034 at a notable CAGR. The United States holds the largest market share compared to EU4 (Germany, Spain, Italy, France), the UK, and Japan.

  • PNP arises from damage to the peripheral nervous system due to factors such as mechanical trauma, metabolic disorders, infections, neurotoxic chemicals, or tumors. Among its various causes, diabetic peripheral neuropathy (DPN) is the most common subtype in the 7MM, followed by lumbosacral radiculopathy (LSR), post-operative and post-traumatic PNP, and chemotherapy-induced peripheral neuropathy (CIPN). Postherpetic neuralgia (PHN), a complication of shingles, is the least prevalent.

  • Treatment options include anticonvulsants, tricyclic antidepressants, and SNRIs, alongside topical agents like capsaicin and lidocaine. Nonpharmacological approaches, such as physical therapy and TENS, complement drug therapies. Approved treatments include QUTENZA, NUCYNTA ER, HORIZANT, ZTlido, and TARLIGE.

  • The market is expected to expand significantly with the introduction of emerging therapies, offering novel treatment options. Key pipeline drugs include AP-325, XEOMIN, VX-548, LX9211, HALNEURON, SEMDEXA, and adezunap. Among these, LX9211 and SEMDEXA are projected to lead the market by 2034. However, adezunap faces challenges such as legal restrictions, public stigma, and quality control concerns, limiting its adoption. Meanwhile, ZTlido has captured a substantial share of the lidocaine patch market but may encounter competition from generic alternatives.

  • The market’s growth will primarily be driven by the development of more targeted and personalized therapies addressing both symptoms and underlying causes of PNP.

  • As per DelveInsight analysis, the Peripheral Neuropathic Pain market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Peripheral Neuropathic Pain Market Landscape

Peripheral Neuropathic Pain Overview

Peripheral neuropathies refer to disorders affecting peripheral nerve cells and fibers, arising from various underlying conditions. These nerves include cranial nerves, spinal nerve roots and ganglia, nerve trunks and branches, as well as autonomic nervous system nerves. Peripheral neuropathies are classified into different types, such as mononeuropathies (affecting a single nerve), multiple mononeuropathies or mononeuropathy multiplex (impacting two or more nerves in separate areas), and polyneuropathies (involving widespread nerve damage).

The diverse symptom presentation allows for the identification of distinct clinical phenotypes, which are crucial for guiding diagnostic evaluations. Nerve conduction studies help determine whether the neuropathy is axonal or demyelinating and assess its severity. Additional diagnostic methods, such as genetic testing, cerebrospinal fluid (CSF) analysis, nerve imaging, and nerve biopsy, may be utilized in specific cases to refine diagnosis and treatment approaches.

Do you know the treatment paradigms for different countries? Download our Peripheral Neuropathic Pain Market Sample Report

Peripheral Neuropathic Pain Epidemiology Insights

  • In 2023, the United States reported the highest number of Peripheral Neuropathic Pain (PNP) cases among the 7MM, totaling approximately 35.2 million.

  • Across the 7MM, the highest incidence of severe cases was observed in post-operative and post-traumatic PNP, whereas moderate cases were more prevalent in postherpetic neuralgia (PHN).

Peripheral Neuropathic Pain Epidemiology Segmentation

DelveInsight’s Peripheral Neuropathic Pain market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Peripheral Neuropathic Pain historical patient pools and forecasted Peripheral Neuropathic Pain patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Peripheral Neuropathic Pain Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Peripheral Neuropathic Pain Prevalence

  • Age-Specific Peripheral Neuropathic Pain Prevalence

  • Gender-Specific Peripheral Neuropathic Pain Prevalence

  • Diagnosed and Treatable Cases of Peripheral Neuropathic Pain

Visit for more @ Peripheral Neuropathic Pain Epidemiological Insights

Peripheral Neuropathic Pain Market Outlook

Pharmaceutical companies such as Scilex Holding Company, Grünenthal and Averitas Pharma, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, AstraZeneca, Asahi Kasei Pharma, and Veloxis Pharmaceuticals are actively advancing their lead candidates through various stages of clinical development to explore potential treatments for Peripheral Neuropathic Pain (PNP).

Among emerging therapies, LX9211 and SEMDEXA are anticipated to become market leaders, significantly shaping the PNP market across the 7MM by 2034.

In 2023, opioids dominated the U.S. PNP market, generating approximately USD 2,400 million in revenue, followed closely by NSAIDs at around USD 2,300 million.

Adezunap is expected to see limited adoption in the 7MM due to regulatory challenges, public perception issues, high-risk classification, and quality control concerns related to cannabidiol in emerging markets, all of which impact its market acceptance and manufacturing standards.

Within the EU4 and the UK, NSAIDs contributed the highest revenue in the PNP market, generating approximately USD 600 million in 2023.

Peripheral Neuropathic Pain Marketed Drugs

  • QUTENZA (capsaicin): Grünenthal and Averitas Pharma

  • ZTLIDO (lidocaine): Scilex Pharmaceuticals

Peripheral Neuropathic Pain Emerging Drugs

  • SEMDEXA (SP-102): Scilex Holding Company

  • Adezunap (AP707): Apurano Pharmaceuticals

Peripheral Neuropathic Pain Key Companies

  • Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others

For more information, visit Peripheral Neuropathic Pain Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Peripheral Neuropathic Pain Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Peripheral Neuropathic Pain, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Peripheral Neuropathic Pain epidemiology in the 7MM

  • Peripheral Neuropathic Pain marketed and emerging therapies

  • Peripheral Neuropathic Pain companies

  • Peripheral Neuropathic Pain market drivers and barriers

Table of Contents:

1 Peripheral Neuropathic Pain Market Key Comprehensive Insights

2 Peripheral Neuropathic Pain Market Report Introduction

3 Competitive Intelligence Analysis for Peripheral Neuropathic Pain

4 Peripheral Neuropathic Pain Market Analysis Overview at a Glance

5 Executive Summary of Peripheral Neuropathic Pain

6 Peripheral Neuropathic Pain Epidemiology and Market Methodology

7 Peripheral Neuropathic Pain Epidemiology and Patient Population

8 Peripheral Neuropathic Pain Patient Journey

9 Peripheral Neuropathic Pain Treatment Algorithm, Peripheral Neuropathic Pain Current Treatment, and Medical Practices

10 Key Endpoints in Peripheral Neuropathic Pain Clinical Trials

11 Peripheral Neuropathic Pain Marketed Therapies

12 Peripheral Neuropathic Pain Emerging Therapies

13 Peripheral Neuropathic Pain: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Peripheral Neuropathic Pain

16 Peripheral Neuropathic Pain Market Key Opinion Leaders Reviews

18 Peripheral Neuropathic Pain Market Drivers

19 Peripheral Neuropathic Pain Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Peripheral Neuropathic Pain Epidemiology 2034

DelveInsight’s “Peripheral Neuropathic Pain – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Peripheral Neuropathic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Peripheral Neuropathic Pain Pipeline 2024

“Peripheral Neuropathic Pain Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Peripheral Neuropathic Pain market. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided, which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Neuropathic Pain Market Expected to rise, 2034 | Daiichi Sankyo, Scilex Pharmaceuticals, Azurity Pharmaceuticals, Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex